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Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to
suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated
according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery.
Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gy62 (A) and 1989–92 1.3 Gy62
(B) . Thereafter 1.6 Gy62 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which
30 Gy was administered preoperatively in the ﬁrst two protocols (A and B), while the whole dose was given preoperatively in
the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly.
Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was
death attributed to local failure. Five patients (9%) ‘had a survival’ exceeding 2 years. No signs of local recurrence were seen in
33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C
(P=0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11
out of 14 patients and 17 out of 17 patients, respectively (P=0.005).
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Anaplastic thyroid carcinomas (ATC), in sharp contrast to differen-
tiated thyroid carcinomas, have a poor prognosis (Aldinger et al,
1978; Tan et al, 1995; Ain, 1998). Most patients suffering from
ATC die due to uncontrolled local tumour invasion causing suffo-
cation (Jereb et al, 1975; Junor et al, 1992). ATC is a rare disease
and the vast majority of the patients affected are older than 60
years (Nel et al, 1985; Demeter et al, 1991; Tan et al, 1995; Ain,
1998). Treatment must consequently be governed by conditions
associated with high age. Although patients with ATC can rarely
be cured, every effort should be made to control the primary
tumour and thereby improve the quality of the remaining life.
Surgery, radiotherapy, or chemotherapy used alone is seldom
sufﬁcient to control the disease (Aldinger et al, 1978; Venkatesh
et al, 1990), while a combination of these modalities may improve
local control (Venkatesh et al, 1990; Schlumberger et al, 1991). The
rationale for combining radio- and chemotherapy is that, as the
toxicity of these modalities does not entirely overlap, an enhanced
tumouricidal effect may be obtained (Wendt et al, 1985).
The most effective and most commonly used single cytostatic
agent against thyroid carcinomas is doxorubicin (Ekman et al,
1990). The combination of doxorubicin and radiation in mamma-
lian tumour cells is synergistic when a low dose of this cytostatic
agent (50.15 mg kg
71) is used (Byﬁeld et al, 1977). The mechan-
ism responsible for the radiosensitising effect of doxorubicin is a
subject of speculation (Rosenthal and Rotman, 1991).
Hyperfractionated radiotherapy can reduce the early reaction in
normal tissues (Withers, 1985; Rosenthal and Rotman, 1991). As
ATC is a rapidly growing tumour, it may be important to decrease
the ‘overall treatment time’ by accelerating the fractionation of the
radiotherapy regimen, thereby reducing the opportunity for
tumour cells to repopulate during the course of treatment (Thames
et al, 1982). Moreover, surgery can remove the large necrotic
tumour mass, which theoretically may enhance the efﬁcacy of the
other treatment modalities (Schlumberger et al, 1991).
Based on the above rationale, we have prospectively evaluated a
combined regimen consisting of hyperfractionated radiotherapy,
doxorubicin, and, when feasible, debulking surgery in 55 consecu-
tive patients presenting with ATC. The hyperfractionated
radiotherapy was gradually accelerated in each of the three proto-
cols evaluated, while the total radiation dose remained the same.
The main purpose of this present study, which is to our knowledge
the largest prospective study of ATC, was to improve the local
control rate, a prerequisite for cure and decent quality of life.
PATIENTS
Between August 1984 and January 1999, 67 consecutive patients
with ATC, cytologically veriﬁed by ﬁne-needle aspiration, were
referred to the Departments of Oncology in Lund (n=35) or in
C
l
i
n
i
c
a
l
Received 11 December 2001; revised 27 March 2002; accepted 12 April
2002
*Correspondence: J Tennvall; E-mail: Jan.Tennvall@onk.lu.se
British Journal of Cancer (2002) 86, 1848–1853
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comStockholm, Radiumhemmet, (n=32). Fifty-ﬁve patients entered one
of the three sequential protocols. The reasons for excluding 10
patients were: refusal to accept treatment (n=1), lack of co-opera-
tion due to senility (n=2); major protocol violations (n=4); and a
discrepancy between the diagnosis based on aspiration cytology and
subsequent histopathologic ﬁndings at surgery (n=3). In these three
cases the histologic diagnosis was a poorly differentiated thyroid
carcinoma, a poorly differentiated medullary thyroid carcinoma,
and a poorly differentiated metastasis. This discrepancy in diagno-
sis may be due to therapeutic eradication of microscopic foci of
anaplastic carcinoma in the poorly differentiated thyroid carcino-
ma. This diagnostic approach meant that a few patients with
poorly differentiated carcinomas received preoperative chemo-
and radiotherapy. The alternative approach of a diagnostic surgical
biopsy would have resulted in a delay in the initiation of therapy
because of poor healing of the surgical scar.
At the time of presentation each of the 55 patients had a rapidly
enlarging neck mass. In 13 patients, a nodular goitre had been
previously recognised. Due to the enlarging thyroid mass, patients
had symptoms from compression or invasion of the upper aerodi-
gestive tract such as dyspnea (n=16), dysphagia (n=13), hoarseness
(n=11), and local pain (n=7). The median duration of symptoms
prior to diagnosis was 1.5 months (range, 0–8 months).
Table 1A–C presents the patient characteristics and the tumour
extension at the start of therapy. Ages ranged between 46 and 94
years (median 76) with a preponderance of females (n=38 vs
n=17). The large thyroid tumours often extended into surrounding
tissues (T4; n=51), making preoperative evaluation of regional
lymph nodes difﬁcult. Eighteen of the patients with T4 tumours
had vocal cord paralysis. The remaining four patients (Patients 2,
23, 24 and 32 in Table 1) had large but intrathyroidal tumours
(T3).
Tumour volume was estimated prior to the start of treatment
according to the formula for a rotating ellipsoid (volume=-
length6width
2/2), which gives a good approximation of tumour
weight. The estimated tumour volume was less than 50 ml in 12
patients, 50–200 ml in 22 patients, and exceeded 200 ml in 21
patients.
At diagnosis, the disease was limited to the neck in 38 patients,
while pulmonary metastases were diagnosed in the remaining 17
patients. In our experience, surgical biopsy delays the initiation
of therapy due to poor healing of the surgical scar (Nilsson et al,
1998), and as cytology is reliable in diagnosing ATC (Lo ¨whagen
et al, 1981; A ˚kerman et al, 1985), the diagnosis in 51 of the 55
patients was established by ﬁne-needle aspiration. On entering
the study, only two patients had received any previous anti-tumour
therapy. In these two patients (Patients 2 and 11), the initial treat-
ment was surgery and subsequent histopathology provided the
diagnosis. All patients were reevaluated with regard to the diagnosis
including a review of all histopathologic specimens. In a few
doubtful cases, additional immunocytochemistry conﬁrmed the
epithelial origin of the tumours. Classiﬁcation was made according
to the World Health Organisation (WHO) criteria. If the patients
did undergo surgery, the diagnosis was based on the results of
the aspiration cytology and the clinical data.
METHODS
After the diagnosis of ATC had been established cytological, ther-
apy was started immediately with informed consent being given
by all 55 patients. The treatment regimens are presented in Figure
1: A, patients 1–16 treated in 1984–1988, B, patients 17–33, trea-
ted in 1989–1992 and C, patients 34–55, treated in 1993–1999.
Preliminary data for Protocols A and B have been presented earlier
(Tennvall et al, 1994). The combined treatment consisted of hyper-
fractionated radiotherapy, doxorubicin, and when feasible, surgery.
A dose of 20 mg doxorubicin was administered once weekly prior
to the ﬁrst radiotherapy session.
In Protocol A radiotherapy was administered preoperatively to a
target dose of 30 Gy during 3 weeks and an additional 16 Gy post-
operatively during 1.5 weeks, resulting in a total target dose of
46 Gy within 70 days. It was administered twice daily, 5 days a
week, with a target dose of 1 Gy per fraction and with a minimum
interval of 6 h.
In Protocol B hyperfractionated radioptherapy was accelerated
by administering a target dose of 1.3 Gy per fraction twice daily
to the same total doses pre- and postoperatively. The overall
treatment time for the local therapy was consequently shortened
to approximately 50 days but radiotherapy was otherwise the
same.
In Protocol C, the radiotherapy was further accelerated by
increasing the target dose to 1.6 Gy/fraction twice daily and admin-
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Table 1A Series A (patients 1–16)
Patient Sex/ Tumour Preop. RT+ Total dose of
no. age volume (cm
3) T:M Postop. RT (Gy) Surgery doxorubicin (mg) Follow-up
Alive:
1 M/69 550 4:0 30+16 + 1400 NED at 156 months
Death attributed to:
2 F/80 100–150 3:0 0+30 + 1095 IC, but NED at 64 m
3 F/85 4200 4:0 30+16 + 780 M+, no local disease at 21 months#
4 F/79 50–100 4:0 30+20 + 120 M+, no local disease at 12 months
5 F/72 50–100 4:0 30+16 + 75 M+, no local disease at 3 months
6 M/83 50–100 4:+ 30+16 7 160 M+, but PLD at 3 months
7 M/77 100–150 4:+ 30+0 7 40 M+, but PLD at 0 months
8 F/74 4200 4:+ 28+0 7 60 M+, but PLD at 2 months
9 M/81 550 4:0 30+16 + 380 IC (M0), but PLD at 6 months
10 F/94 550 4:+ 30+16 7 140 IC (M+), but PLD at 3 months
11 M/69 150–200 4:0 0+31 + 80 LF (M+) at 2 months
12 F/65 4200 4:0 30+16 +* 160 LF (M0) at 5 months
13 F/89 50–100 4:0 30+16 +* 60 LF (M0) at 4 months
14 F/81 4200 4:+ 30+16 7 200 LF (M+) at 4 months
15 F/75 4200 4:+ 30+0 7 40 LF (M+) at 2 months
16 M/60 4200 4:0 30+0 7 60 LF (M+) at 1 months
RT=radiotherapy; LF=local failure; PLD=persistent local disease; M+=distant metastases; IC=intercurrent disease; NED=no evidence of
disease; S+=surgery performed; *=visible tumour remaining after surgery; #Died due to distant metastases of a coexisting oxyphil
carcinoma.
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(1.6 Gy62 per day) within 3 weeks. Since the radiotherapy was
accelerated, the minimum interval of 6 h between the two fractions
was even more important so as to prevent spinal cord myelopathy
(Dische and Saunders, 1989; Wong et al, 1991).
The patients were treated in the supine position. Two opposed
ﬁelds (AP–PA) were used, encompassing, in addition to the thyr-
oid tumour (target 1), the regional lymph nodes of the neck, the
supraclavicular areas, and the upper mediastinum (target 2). Spinal
cord shielding was used in the posterior portal during postopera-
tive radiotherapy. The radiotherapy was delivered with a high-
voltage technique (60 Co, 4 MV, or 6 MV photons). If the tumour
had inﬁltrated superﬁcial tissues, a bolus was used. The dose to
target 1 was estimated to vary from 46 to 50 Gy, except behind
the spinal cord shield, where the dose was 3–4 Gy lower (viz a
maximum dose of 46 Gy in all three protocol). This implied a total
variation of the speciﬁcation dose within target 1 ranging from
78% to +10%.
C
l
i
n
i
c
a
l
Table 1C Series C (patients 34–55)
Patient Sex/ Tumour Preop. RT+ Total dose of
no. age volume (cm
3) T:M Postop. RT (Gy) Surgery doxorubicin (mg) Follow-up
Alive:
34 F/78 100–150 4:0 46+0 + 320 Alive NED at 49 months
Death attributed to:
35 F/84 100–150 4:0 46+0 +* 60 IC, no local disease at 3 months
36 M/66 4200 4:0 46+0 + 80 IC, no local disease at 2 months
37 F/83 4200 4:+ 46+0 + 60 M+, no local disease at 2 months
38 F/81 50–100 4:0 46+0 + 60 M+, no local disease at 3 months
39 M/78 4200 4:+ 46+0 + 160 M+, no local disease at 2 months
40 F/70 4200 4:0 46+0 + 400 M+, no local disease at 15 months
41 F/66 550 4:0 46+0 + 360 M+, no local disease at 8 months
42 M/49 50–100 4:0 46+0 + 320 M+, no local disease at 13 months
43 M/82 550 4:0 45+0 + 60 M+, no local disease at 2 months
44 F/83 50–100 4:0 46+0 +* 60 M+, no local disease at 2 months
45 M/85 4200 4:0 47+0 + 60 M+, no local disease at 4 months
46 F/71 50–100 4:0 46+0 + 60 M+, no local disease at 2 months
47 M/71 550 4:+ 46+0 + 80 M+, no local disease at 2 months
48 M/72 150–200 4:0 42+0 + 100 M+, no local disease at 4 months
49 M/67 150–200 4:+ 46+0 + 200 M+, no local disease at 4 months
50 F/61 550 4:+ 46+0 + 60 M+, no local disease at 1 months
51 F/89 550 4:+ 46+0 7 60 LF (M+) at 1 months
52 F/84 4200 4:0 46+0 7 60 LF (M+) at 1 months
53 F/85 4200 4:0 40+0 7 40 LF (M+) at 0 months
54 M/79 4200 4:+ 34+0 7 60 LF (M+) at 0 months
55 F/63 4200 4:0 46+0 7 60 LF (M+) at 1 months
RT=radiotherapy; LF=local failure; PLD=persistent local disease; M+=distant metastases; IC=intercurrent disease; NED=no evidence of
disease; S+=surgery performed; *=visible tumour remaining after surgery.
Table 1B Series B (patients 17–33)
Patient Sex/ Tumour Preop. RT+ Total dose of
no. age volume (cm
3) T:M Postop. RT (Gy) Surgery doxorubicin (mg) Follow-up
Alive:
17 F/75 50–100 4:0 31+15 + 360 NED at 102 months
18 F/69 4200 4:0 30+16 + 380 NED at 65 months
Death attributed to:
19 F/74 550 4:0 31+15 + 380 M+, no local disease at 8 months
20 M/80 50–100 4:0 30+16 + 260 M+, no local disease at 4 months
21 F/60 4200 4:0 30+16 + 215 M+, no local disease at 5 months
22 M/46 4200 4:+ 30+0 + 60 M+, no local disease at 2 months
23 F/85 50–100 3:0 30+16 + 80 M+, no local disease at 5 months
24 F/83 100–150 3:0 30+16 + 240 M+, no local disease at 11 months
25 F/77 50–100 4:0 30+0 + 60 M+, no local disease at 4 months
26 F/71 550 4:+ 30+16 + 140 M+, no local disease at 3 months
27 F/77 50–100 4:0 30+0 +* 60 IC (M+), no local disease at 2 months
28 F/61 550 4:0 30+0 + 100 M+, but PLD at 6 months
29 F/61 4200 4:0 30+16 +* 100 M+, but PLD at 2 months
30 F/74 550 4:+ 30+0 7 60 M+, but PLD at 1 months
31 F/76 4200 4:+ 30+0 7 60 M+, but PLD at 1 months
32 F/78 150–200 3:0 30+16 + 670 LF (M0) at 13 months
33 F/76 4200 4:0 30+16 7 80 LF (M0) at 2 months
RT=radiotherapy; LF=local failure; PLD=persistent local disease; M+=distant metastases; IC=intercurrent disease; NED=no evidence of
disease; S+=surgery performed; *=visible tumour remaining after surgery.
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the planned operation was abandoned in Protocols A and B, the
second course of radiotherapy was started within 3 weeks. In
Protocol C all planned radiotherapy was administered in one series
preoperatively and further radiotherapy was in no case considered.
The two patients (numbers 2 and 11) who had undergone prior
surgery in Protocol A received only one course of postoperative
hyperfractionated radiotherapy to a dose of 30 Gy, in combination
with doxorubicin (Table 1).
After the completion of the local treatment, the weekly admin-
istration of doxorubicin at 20 mg i.v. was continued in patients
showing sufﬁciently good performance (Table 1). The upper sched-
uled level of doxorubicin was 750 mg m
2 in Protocol A. The
schedule for Protocols B and C was doxorubicin therapy for a
maximum of 3 months after termination of the local therapy corre-
sponding to a total dose of 430–450 mg. Statistical comparisons
were performed with Fisher’s exact test (two-sided) and the w
2 test
for trend (Altman, 1991).
RESULTS
Feasibility
All three protocols could be carried out. Local toxicity: the forms
of acute toxicity observed were mucosal and skin reactions corre-
sponding to WHO grades 1 or 2 apart from four patients; one
each in Protocols A and B and 2 in Protocol C. Two of these
patients (belonging to Protocol A and B) required a break of 1–
1.5 weeks before resumption of therapy and one patient required
an enteral tube after termination of the therapy. Thus, all but these
four patients with oesophagitis WHO grade 3 (n=3) or grade 4
(n=1) could eat solid food.
No signs of neurological toxicity was observed. One patient in
Protocol C exhibited transient haematological toxicity upon termi-
nation of radiotherapy (leukocytes 1.8, thrombocytes 86), which
was resolved after a week. No patient failed to complete the treat-
ment due to toxicity. Disease progression or deterioration in
performance were reasons for not completing the treatment sched-
uled.
In 40 patients (nine in Protocol A, 14 in Protocol B, and 17 in
Protocol C) surgery was performed and radiotherapy and
chemotherapy were administered. The other 15 patients (seven
in Protocol A, three in Protocol B, and ﬁve in Protocol C)
received a combination of chemotherapy and radiotherapy only.
Surgery was considered microscopically radical in the four
patients with a large T3 tumour (Patients 1, 23, 24, and 32),
marginal in 30 patients (six in Protocol A, nine in Protocol B,
and 15 in Protocol C), and not radical (visible residual tumour)
in six patients (two in each protocol). The preoperative doxorubi-
cin administration together with concomitant hyperfractionated
radiotherapy thus converted generally unresectable tumours into
resectable tumours.
After completion of the local therapy, 22 patients (six in
Protocol A, seven in Protocol B, and nine in Protocol C) were
able to continue with doxorubicin treatment (20 mg i.v. weekly)
(Table 1).
Survival
The median survival was 3.5 months (range 0–156) in Protocol
A, 4.5 months in Protocol B (range 0–102), and 2 months in
Protocol C (range 0–28). The numbers of patients with distant
metastases at diagnosis were 6, 4, and 7, in Protocols A, B and
C, respectively. Nine patients (16%) survived for over a year,
evenly distributed between the three series. Only one of these
nine patients died due to local failure (at 13 months; Protocol
B). Two patients died due to distant metastases at 13 months
and 15 months, and one patient due to subcutaneous metastases
of a coexisting oxyphil carcinoma (Azkanazy cell cancer) at 21
months. All ﬁve patients (9%) who survived longer than 2 years
(49 months+, 64 months, 65 months+, 102 months+,
156 months+) showed no signs of recurrence. The poor survival
in Group C of only 2 out of 22 (9%) patients was disappointing
with respect to the improved local control.
All these patients had received the prescribed regimen including
surgery, except for Patient 2 (Protocol A), who had a large
intrathyroidal tumour. All the other patients had tumours with
extrathyroidal growth, for which surgery was considered marginally
radical. The initial and also predominant site of metastases was
always the lungs. Death resulting from intercurrent disease was
attributed in two cases to cardiovascular disease (Numbers 10
and 27), and in the remaining cases to infections. No apparent
relation between deaths attributed to intercurrent disease and ther-
apy seemed to exist.
Local tumour control
The individual local tumour response to the three regimens
employed is presented in Table 1. Death due to local failure
occurred in 13 (24%) of the 55 patients evaluated (in Protocol A
6 out of 10; B 2 out of 17; C 5 out of 22). Conversely, there were
no signs of local remnant tumour or local recurrence in 33 (60%)
of the patients distributed as follows: ﬁve out of 16 in Protocol A,
11 out of 17 in Protocol B, 17 out of 22 in Protocol C. This indi-
cates a strong correlation between local tumour control and
acceleration of radiotherapy (Fisher’s exact test P=0.017; w
2 test
for trend P=0.004). The improved local control could not be
attributed to any differences in terms of local tumour extension
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Treatment protocol A
Radiotherapy
(Gy/fractions)        30 Gy/30 fractions                                          16 Gy/16 fractions
Adriamycin
20 mg i.v. weekly
Surgery (S) S
0 1  2  3  4  5  6  7  8       9  10
Treatment protocol B
Radiotherapy
(Gy/fractions)      30 Gy/23 fractions                         16 Gy/12 fractions
Adriamycin
20 mg i.v. weekly
Surgery (S) S
Treatment protocol C
Radiotherapy
(Gy/fractions)      46 Gy/29 fractions
1.6 Gy ´ 2/day
Doxorubicin
20 mg i.v. weekly
Surgery (S) S
Weeks
Weeks
Weeks
012  3 4 5678
0 1 2 3 4 5  
Figure 1 Treatment protocol for the three consecutive series A, B and
C.
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operated on. Additional surgery was, however, a prerequisite for
eradication of local disease.
In the 40 patients undergoing additional surgery, 33 patients
(83%) showed no signs of local recurrence. The local control varied
signiﬁcantly between the three protocols. In Protocol A, 5 out of 9
did not show any signs of local recurrence, while the corresponding
ﬁgures in Protocol B and C were 11 out of 14 and 17 out of 17,
respectively (Fisher’s exact test P=0.005; w
2 test for trend
P=0.015). Although additional surgery was a prerequisite for local
tumour control, the trend analysis demonstrated that improved
local tumour control was correlated to more accelerated therapy,
also when surgery was taken into consideration. It should be
emphasised that none of the 17 patients in Protocol C had a local
tumour remnant or local recurrence when surgery was feasible. On
the other hand, in Protocol A two patients with pulmonary metas-
tases at diagnosis (Patients 14 and 15) did not undergo surgery and
ﬁnally succumbed due to local failure.
DISCUSSION
The primary aim of preventing patients with ATC from dying
due to suffocation caused by local tumour invasion, was
achieved in Protocol C. The present multimodal treatment of
ATC seems to be feasible and effective, despite the patients’ high
age and locally advanced disease. There was a signiﬁcant positive
correlation between accelerated radiotherapy and local tumour
control. None of the 17 patients in Protocol C, i.e. receiving
the most accelerated hyperfractionated radiotherapy, and subse-
quent surgery had a local remnant tumour or suffered local
recurrence.
Macroscopically radical surgery is a prerequisite for local cure,
since all 33 patients showing no signs of remnant or recurrent local
tumour growth had had surgery. It appears that the surgery does
not need to be microscopically radical as only three fulﬁlled this
criterion; one in Protocol A, and two in Protocol B. A conceivable
alternative to a preoperative radiation dose of 46 Gy would be a
dose of 68–70 Gy with the same fractionation (1.6 Gy62) but
without succeeding operation. Such an alternative would probably
not be feasible for this elderly patient population and furthermore
the eradication of large thyroid tumours would probably be less
effective than that of the present multimodal strategy (Mitchell et
al, 1999).
No differentiated thyroid carcinomas with small anaplastic foci,
which have a more favourable prognosis, were included in the
present study. Although only advanced ATC were included, nine
patients (16%) had a survival exceeding one year. All ﬁve patients
(9%) with a survival exceeding 2 years seem to be cured.
Regardless of the poor prognosis for ATC, the possibility of
saving patients from suffocation justiﬁes the combined local treat-
ment, also in selected patients with metastatic disease.
We have shown that weekly doxorubicin (20 mg) therapy
could be performed without severe toxicity within a multimodal
approach, even when the most accelerated hyperfractionated
radiotherapy (1.6 Gy62/day) was used. In a previous study,
performed at the same centres, presented by Werner et al
(1984) and reviewed by Nilsson et al (1998), the same regimen
as that used in Protocol A (1 Gy62/day) in the current study,
apart from the chemotherapy, was employed. The chemotherapy
then consisted of BCF (bleomycin, 5 mg day 1, cyclophospha-
mide 200 mg day 1, 5-ﬂuorouracil, 500 mg every other day).
Only nine out of 25 (36%) patients died of local failure in that
study. Three patients were considered cured after a follow-up of
6 years with no recurrence. Several of the patients included
suffered from severe therapy-related toxicity (epithelitis or muco-
sal ulcerations in the mouth and throat) which caused
interruptions of the treatment. Following a report by Kim and
Leeper (1983), we replaced the BCF with weekly administered
doxorubicin. In addition to weekly doxorubicin, Kim and Leeper
(1983; 1987) used hyperfractionated but not accelerated radio-
therapy, and reported results similar to those obtained in our
protocol with BCF but with less toxicity. Our aim in this present
study was to prospectively evaluate the treatment and change
only one modality at a time; this practice will enable assessment
of the various components in the multimodality treatment regi-
men.
No response was observed in distant metastases in the present
study, nor in another study employing doxorubicin (60 mg m
2),
cisplatin (90 mg m
2) and local radiation (Schlumberger et al,
1991). The use of a more aggressive cytostatic regimen in a
multimodal approach is therefore not justiﬁed, except possibly
in younger subjects in good performance upon termination of
local therapy. Such a strategy would not compromise the
completion of the local therapy, which, however, comes into
conﬂict with starting the systemic therapy when the metastases
are still small or not yet apparent. The observed relative ineffec-
tiveness of antineoplastic agents in ATC suggests an active role
for one or more cellular mechanisms associated with chemother-
apy resistance (Satake et al, 1997; Ain, 1998). Apart from
providing an explanation of the failure of systemic chemother-
apy, such mechanisms might provide appropriate targets for
inactivation in order to restore clinical response to standard
chemotherapies (Ain, 1998).
Although no form of chemotherapy has yet been found to result
in improvement in survival or to have a substantial effect on estab-
lished metastases, new chemotherapeutic agents should be tested
(Ain, 1998). New modalities such as inhibitors of angiogenesis,
might in the future, also prove to be useful tools for control of
the growth of ATC (Hama et al, 1997).
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